Intercept Pharma (ICPT): AASLD Meeting Takeaway - Needham

November 16, 2016 6:38 AM EST
Get Alerts ICPT Hot Sheet
Price: $102.74 -0.77%

Rating Summary:
    17 Buy, 3 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade ICPT Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Needham & Company analyst, Alan Carr, reiterated his Buy rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) after the company presented additional analyses of Ocaliva clinical data as well as preclinical INT-767 data at recent AASLD mtg. Behind Genfit and Intercept, several companies are bringing new candidates forward in NAFLD/ NASH and have begun presenting clinical data.

The analyst believes multiple candidates have an encouraging impact on some histology parameters, but it is too early to tell if any will emerge as viable safe and effective drugs. The analyst stated "we note Intercept and Tobira/ Allergan have shown statistically significant improvements in fibrosis and Gilead recently reported encouraging impact on fibrosis w/ selonsertib. A range of mechanisms are under exploration, including several non-steroidal FXR agonists. Although there were a large number of HCV presentations at the mtg, a shift towards NAFLD/ NASH is increasingly evident."

No change to the price target of $350.

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $113.51 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

Needham & Company, Alan Carr

Add Your Comment